Cost-effectiveness of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada
Canadian Medical Association Journal · 2026
DOI: 10.1503/cmaj.250591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Medical Association Journal, 2026. Verfasst von Ethan S McNally und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Economics (McNally), and School of Population and Global Health (McNally, Russell), McGill University; DREAM-CV Lab (Marques, Possik, S…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Diabetes Canada and the Canadian Cardiovascular Society recommend that patients with type 2 diabetes and cardiovascular disease, renal disease, or multiple cardiovascular risk factors begin glucagon-like peptide-1 receptor agonists (GLP-1 RA) or sodium-glucose cotransporter 2 inhibitors (SGLT2i). We assessed cost-effectiveness in patients meeting these criteria in Canada. METHODS: Our patient-level simulation estimated lifetime costs, clinical events, and quality-adjusted life-years (QALYs) for patients initiating SGLT2i or GLP-1 RA or remaining on "baseline treatment"; i.e., other standard-of-care medications. We based initial laboratory values and characteristics on 216 patients from a Quebec clinic focused on initiating guideline-directed diabetes therapies from 2022 to 2025. We calibrated risk equations and treatment effects to end points from placebo-controlled cardiovascular outcome trials. We estimated cost-effectiveness over a patient lifetime horizon from a Canadian health care payer perspective using a 1.5% annual discount rate. We performed probabilistic sensitivity analysis. RESULTS: Compared with baseline treatment, SGLT2i and GLP-1 RA reduced lifetime rates of cardiovascular and renal events and produced higher net present QALYs (+0.24 SGLT2i; +0.23 GLP-1 RA ), but at a higher net present cost (+$5000 SGLT2i; +$27 000 GLP-1 RA [2023 Canadian $]). Sodium-glucose cotransporter 2 inhibitors cost $21 400 per QALY gained and were consistently cost-effective in sensitivity analyses. In 62% of probabilistic sensitivity analysis iterations, GLP-1 RA were dominated, producing fewer QALYs at a higher cost than SGLT2i. INTERPRETATION: Sodium-glucose cotransporter 2 inhibitors provided more QALYs at a lower price than GLP-1 RA and were cost-effective at current prices. Glucagon-like peptide-1 RA cost-effectiveness may improve if outcomes beyond typical diabetes complications are considered and if generic GLP-1 RA become available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Economics (McNally), and School of Population and Global Health (McNally, Russell), McGill University; DREAM-CV Lab (Marques, Possik, Sharma), Research Institute of the McGill University Health Centre (MUH…
Zitieren
APA
McNally, E. S., Marques, P., Possik, E., Pandya, A., Tsoukas, M. A., Mavrakanas, T. A., Dasgupta, K., Gupta, N., Sharma, A., & Russell, W. A. (2026). Cost-effectiveness of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada. Canadian Medical Association Journal. https://doi.org/10.1503/cmaj.250591
Vancouver
McNally ES, Marques P, Possik E, Pandya A, Tsoukas MA, Mavrakanas TA, et al. Cost-effectiveness of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada. Canadian Medical Association Journal. 2026. doi:10.1503/cmaj.250591
BibTeX
@article{McNally2026,
author = {McNally, Ethan S and Marques, Pedro and Possik, Elite and Pandya, Ankur and Tsoukas, Michael A and Mavrakanas, Thomas A and Dasgupta, Kaberi and Gupta, Nisha and Sharma, Abhinav and Russell, W Alton},
title = {Cost-effectiveness of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada},
journal = {Canadian Medical Association Journal},
year = {2026},
doi = {10.1503/cmaj.250591}
}
EUVIMED